Mastering Wind Power Online Workshop is Back by Popular Demand ACN Newswire

Mastering Wind Power Online Workshop is Back by Popular Demand

January 26, 2023
Singapore, Jan 26, 2023 - (ACN Newswire via SEAPRWire.com) - Infocus International Group, a global business intelligence provider of strategic information and professional services, has announced the new dates for Mastering Wind Power training and it will be commencing live on the 20th of February 2023. Attendees will gain an excellent understanding of all the key factors facing wind power developers and investors, from resource assessment and energy production complexities, through technology trends, project development and planning challenges, to financial returns and risks.The course will include the illustration of key concepts using online tools, wind resource datasets, energy yield, financial and other simple calculations, along with discussion of key planning and market environment considerations.In keeping with the business-focused theme of the course, any illustrative materials are designed to provide time-efficient clarification of the key course takeaways, aimed at commercially-focused business developers and investors. They are therefore accessible to non-experts, not designed to replicate the complex or in-depth detailed planning undertaken - over much longer periods! - by experienced engineers and technical teams.A past participant from Statkraft Development AS shared, "This was one of my best spent weeks on training all year! A good and efficient way of getting an overview of the renewable energy sector. I found him very knowledgeable and enthusiastic in presenting the material, also enabling knowledge exchange between participants in the group. I really enjoyed his interesting lessons and the group work he provided for additional learning outcomes. Thanks.""Execellent course. It is very helpful to me to understand how to develop and construct the wind farm project," said another past participant from Mitr Phol Group.Course Sessions1. From wind flow to electricity: wind turbines and wind farms2. Understanding and measuring wind resources3. Successful delivery of wind power projects4. Taking wind power offshore5. Making money from wind power projectsAmong the key points to be addressed- Learn from global experiences in wind power project development- Understand unique properties of wind resource, and how these feed into financial risk analysis- Gain a business-focused, up-to-date perspective on current and emerging wind technology innovations and project delivery best practices- Analyse and discuss practical and project delivery risks facing wind power projects, including key stakeholder engagements- Get hands-on with a financial model to better understand financial risks and returns for wind power projects- Compare and contrast the unique extra costs and complexities of offshore wind projects with those onshoreWant to learn more?Simply email to esther@infocusevent.com or call +65 6325 0210 to obtain your FREE COPY of event brochure. For more information, please visit www.infocusinternational.com/wind-online.About Infocus International GroupInfocus International is a global business intelligence provider of strategic information and professional services for diverse business communities. We recognises clients' needs and responds with innovative and result oriented programmes. All products are founded on high value content in diverse subject areas, and the highest level of quality is ensured through intensive and in-depth market research from local and international insights. For more information: www.infocusinternational.com Copyright 2023 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Malaysian Genomics Signs MoU with Ajlan to explore distribution of biopharmaceutical and genetic screening services in MENA region ACN Newswire

Malaysian Genomics Signs MoU with Ajlan to explore distribution of biopharmaceutical and genetic screening services in MENA region

August 29, 2022
PETALING JAYA, Malaysia, Aug 29, 2022 - (ACN Newswire via SEAPRWire.com) - Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, today announced that the Group has signed a Memorandum of Understanding (MoU) to explore opportunities for the distribution of biopharmaceutical and genomics products and services with Ajlan & Bros Medical Company.Noor Azri Bin Dato' Sri Noor Azerai, Executive Director of Malaysian Genomics, and H.E. Eng. Ali AlHazmi, Group Chief Executive Officer of Ajlan & Bros Holding Group [L-R]Ajlan, based in Riyadh, Saudi Arabia, is part of a multinational conglomerate established in 1979 with extensive global private equity, real estate and industrial investments.As part of the MoU, the parties will explore the feasibility of Ajlan becoming a marketing and distribution representative for Malaysian Genomics for genetic screening tests, mesenchymal stem cell and exosome products. Ajlan will also identify commercial research and development (R&D) opportunities for genome sequencing and analysis in the Middle East and North Africa (MENA) region for areas such as agriculture, aquaculture, plantations, healthcare and industrial biotechnology.Malaysian Genomics on its part will analyse samples for genetic screening tests as well as provide Ajlan with genomic and bioinformatics expertise to bid for projects through Ajlan.Noor Azri Bin Dato' Sri Noor Azerai, Executive Director of Malaysian Genomics, said, "This is a really good opportunity for us to explore the MENA market for our products and services, especially in the area of R&D where we see a lot of growth especially in agriculture and aquaculture due to climate change impact and the health diagnosis for distinct population groups."H.E. Eng. Ali AlHazmi, Group Chief Executive Officer of Ajlan & Bros Holding Group, said, "We look forward to working with Malaysian Genomics to bring its biopharmaceutical and genetic services and products to Saudi Arabia, which is a good launchpad to the MENA region. This MoU is just the beginning as we explore how we can work closely together in the coming months."About Malaysian Genomics Resource Centre BerhadMalaysian Genomics Resource Centre Berhad ("Malaysian Genomics" or "the Group") is a leading genomics and biopharmaceutical company based in Southeast Asia. The Group was established in 2004 and listed on the Bursa Malaysia stock exchange in 2010. From pioneering work in genome sequencing, bioinformatics analysis, and genetic screening services, Malaysian Genomics has expanded into the biopharmaceutical sector with the manufacturing of cell therapies including immunotherapy for various types of cancer.Utilising its high-throughput sequencing lab, advanced microarray facility, and new state-of-the-art cell processing lab, the Group is committed to improving access to the latest in precision and personalised healthcare solutions to improve the lives of patients. For more information, visit www.mgrc.com.my. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
UCrest Partners with Malaysian Genomics to Digitalize Genome Services Worldwide ACN Newswire

UCrest Partners with Malaysian Genomics to Digitalize Genome Services Worldwide

July 20, 2022
PETALING JAYA, Malaysia, Jul 20, 2022 - (ACN Newswire via SEAPRWire.com) - UCrest Berhad (ACE Market: 0005) and Malaysian Genomics Resources Centre Berhad, (ACE Market: 0155) announced today that they have signed a collaborative agreement to integrate genomic testing services into digital health platform, iMedic(TM), elevating healthcare services to the next level.Dato' Dr. Mohd Fikri bin Abdullah, Independent Director of UCrest Berhad; Mr. Eg Kah Yee, Chairman and Managing Director of UCrest Berhad; En. Sasha Nordin, Chief Executive Director, Malaysian Genomics Resource Centre Berhad; Dr. Eunice Pui Wan Wen, Head of Medical Affairs, Malaysian Genomics Resource Centre Berhad[L-R]Dato' Dr. Mohd Fikri bin Abdullah, Independent Director of UCrest Berhad; Mr. Eg Kah Yee, Chairman and Managing Director of UCrest Berhad; En. Sasha Nordin, Chief Executive Director, Malaysian Genomics Resource Centre Berhad; Dr. Eunice Pui Wan Wen, Head of Medical Affairs, Malaysian Genomics Resource Centre Berhad[L-R]Under this agreement, a virtual genome service centre will be developed on iMedic platform enabling the genomic testing services of MGRC to be made available to the hospitals and clinics (B2B), widening its market access not just in Malaysia, but globally. Additionally, the genomic testing services will also be made available to patients directly (B2C). Patients' genomic data from their test results will be integrated into Electronic Medical Records (EMR) making it accessible by doctors and patients in the process of consultation and management, resulting in improved accuracy in diagnosis and treatment.UCrest is the leading technology provider of digital health platform with offices in Malaysia, Singapore, China and Taiwan providing access to thousands of doctors, including many from the leading hospitals in the United States and China, to provide online consultation and management of patients anywhere in the globe.Malaysian Genomics is a leading genomics and biopharmaceutical company in ASEAN for genome sequencing, bioinformatics analysis, and genetic screening, and various types of immunotherapy including CAR T-Cell therapy for the treatment of certain cancers.The global genomics market size was valued at US$20.1 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 15.35% from 2021 to 2028. The Asia Pacific genome sequencing market will grow by 15.6% annually over 2022-2030 due to growing government funding initiatives in genomics projects related to cancer treatment and the utilization of genomics in personalized medicine targeting chronic disease prevention and management.Mr. Sasha Nordin, Chief Executive Officer of Malaysian Genomics, said, "We are looking forward to working with UCrest as its iMedic platform will provide us an opportunity to reach out to markets beyond Malaysia. The platform will also enable us to strengthen our B2B and B2C channels. This collaboration can play an important role in providing physicians with easy access to the latest in genetic screening, in support of enhancing their medical practice and improving patient outcomes.""This partnership with Malaysian Genomics allows us to enhance our vision of integrating preventive and precision medicine into iMedic where genome data will empower the patients to better prevent and manage the chronic diseases with the online consultation of doctors," said Mr. Eg Kah Yee, Chief Executive Officer of UCrest. "Cancer, Cardiovascular Diseases (CVD), diabetic, asthma, sleep apnea and many other chronic diseases can be prevented, managed or treated more effectively with the addition of the genome services," he added.Malaysian Genomics Resource Centre Berhad: 0155 [BURSA: MGRC] [RIC: MGRC:KL] [BBG: MGRC:MK], http://www.mgrc.com.my/UCrest Berhad: 0005 [BURSA: UC] https://www.ucrest.net/ Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Malaysian Genomics Forms Partnership for Expansion in Saudi Arabia ACN Newswire

Malaysian Genomics Forms Partnership for Expansion in Saudi Arabia

July 13, 2022
PETALING JAYA, Malaysia, Jul 13, 2022 - (ACN Newswire via SEAPRWire.com) - Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, announced today that it has entered into a strategic partnership with United Doctors Hospital (UDH) for collaboration in genomics and cell therapies.Azri Azerai, Executive Director of Malaysian GenomicsUDH, located in Jeddah, Saudi Arabia, is accredited by the Saudi Central Board for Accreditation of Healthcare Institutions. UDH has also won numerous awards for social responsibility, including the King Khalid Award for Social Responsibility in 2018, and is certified with the SA8000, the world's leading social certification programme, by Social Accountability International (formerly known as Social Accountability Accreditation Services), a United States-based charitable organisation, in 2016.Under the partnership, which is valid for three years, Malaysian Genomics and UDH will take the necessary steps to encourage and promote cooperation in the sales and marketing of genetic screening tests and cell therapy products; collaboration in research and development (R&D), and other areas of cooperation in the genomics and cell therapies to be mutually decided by both parties. Encik Azri Azerai, Executive Director of Malaysian Genomics, said, "This strategic partnership with UDH enables us to expand the geographical reach of our products and services beyond Malaysia to the Middle East and North Africa region. It will also enable us to collaborate on R&D with various domain specialists to enhance our suite of genetic screening tests and cell therapies."Dr. Hefny Moustafa Hefny, Medical Doctor at UDH, said, "Among the areas being explored by Malaysian Genomics and UDH are opportunities to develop genetic screening tests for hereditary conditions and diseases that are prevalent in the Middle East or Northern Africa, which may be different from other parts of the world."Malaysian Genomics is actively expanding its business-to-consumer channels as part of the Group's growth strategy. The Group recently acquired a 51% stake in kidney dialysis operator Aquahealth Sdn Bhd to offer personalised kidney care that also involves nutrition management, lifestyle changes, and genetic testing. It is also collaborating with AirAsia's Asean Super App online shopping platform and Speedoc to provide genetic screening services.Malaysian Genomics Resource Centre Berhad: 0155 [BURSA: MGRC] [RIC: MGRC:KL] [BBG: MGRC:MK], http://www.mgrc.com.my/ Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Malaysian Genomics Proposes Private Placement ACN Newswire

Malaysian Genomics Proposes Private Placement

July 8, 2022
PETALING JAYA, Malaysia, Jul 8, 2022 - (ACN Newswire via SEAPRWire.com) - Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, announced today that the Group is proposing to undertake a private placement of up to 10% of its total number of issued shares or up to 12.42 million new placement shares at an issue price to be determined for third-party investors that will be identified later.Azri Azerai, Executive Director of Malaysian Genomics Resource Centre BerhadShareholders had approved in the AGM convened on 30 November 2021 for the Group to issue and allot new shares at any time and at such price as the Board of Directors deemed fit provided the number of new shares does not exceed 10% of the total number of issued shares. The new placement shares will rank equally in all respects with existing Malaysian Genomics shares except they will not be entitled to any dividends, rights, allotments and any other forms of distribution should the entitlement date precede the relevant date of allotment and issuance of the new placement shares.Encik Azri Azerai, Executive Director of Malaysian Genomics, said, "We are proposing the private placement to raise funds mainly for the Group's future investments of which we are still exploring options and a part of the proceeds will be allocated for the purchase of equipment including IT hardware, biological safety cabinet and extraction automation for our existing and future businesses.""The reopening of the economy presents opportunities in the private healthcare segment and the fresh funds raised will enable us to be able to take advantage of the possibilities. We diversified into the biopharmaceutical business in 2020 and have since been pushing to open channels for our cell therapies and genetic tests through a series of agreements that gives us a wider market reach. We also bought a 51% stake in a kidney dialysis operator, Aquahealth Sdn Bhd, to offer holistic kidney care."UOB Kay Hian Securities (M) Sdn Bhd is the adviser and placement agent for the proposed private placement.Malaysian Genomics Resource Centre Berhad: 0155 [BURSA: MGRC] [RIC: MGRC:KL] [BBG: MGRC:MK], http://www.mgrc.com.my/ Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Malaysian Genomics Resource Centre to Offer Pioneering Holistic Renal Care via New Venture ACN Newswire

Malaysian Genomics Resource Centre to Offer Pioneering Holistic Renal Care via New Venture

June 23, 2022
PETALING JAYA, Malaysia, Jun 23, 2022 - (ACN Newswire via SEAPRWire.com) - Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, announced today that the Group is acquiring a 51% stake in Aquahealth Sdn Bhd, a kidney dialysis operator, from Rinani Renal Berhad.En. Sasha Nordin, Chief Executive Officer of Malaysian GenomicsAquahealth is establishing a kidney dialysis centre in Gombak, Selangor, with the license to operate the centre owned by the Malaysia International Islamic Chamber of Commerce. With the acquisition of the stake, Malaysian Genomics, through its wholly-owned subsidiary, MGRC Healthcare Sdn Bhd, will now become the operator of the dialysis centre.En. Sasha Nordin, Chief Executive Officer of Malaysian Genomics, said, "This will be the first of many centres across the country that will be driven by a personalised kidney care model integrating dialysis with nutrition management, lifestyle changes, and even genetic testing of patients and their immediate family members. This pioneering approach will focus on bringing innovations in service delivery to improve the lives of patients with chronic kidney disease.""Expanding downstream to healthcare services, through our subsidiary MGRC Healthcare, is an important step in Malaysian Genomics' growth as a diversified specialist healthcare group. The acquisition of the Aquahealth stake is part of our Group's strategy to secure a diverse portfolio of earnings accretive assets across Southeast Asia that will, in turn, leverage and benefit from our genomics and biopharmaceutical knowledge and experience developed over the past 18 years."According to the Ministry of Health's Management of Chronic Kidney Disease report, the number of Malaysians with kidney disease is projected to increase significantly in the future mainly due to the prevalence of diabetes, hypertension and an aging population[1]. At 13.2% per year, Malaysia has the second highest annual growth rate of chronic kidney disease in the world[2].Dato' Dr. Suhaini Kadiman, Chairman of Malaysia International Islamic Chamber of Commerce and Director of Clinical Research at Institute Jantung Negara added, "Thousands of kidney patients are on waiting lists for dialysis treatment and new centres are urgently needed. We welcome MGRC Healthcare's interest to collaborate with us to operate the centre in Gombak, and we look forward to the innovations they will contribute to improve the lives of kidney dialysis patients."Recently, Minister of Health YB Tuan Khairy Jamaluddin noted that there were over 40,000 kidney patients in Malaysia, with over 8,000 new patients diagnosed annually since 2018[3].[1] https://tinyurl.com/42jexjsk[2] https://tinyurl.com/2cmkmzkz[3] https://tinyurl.com/mr3mkfmkMalaysian Genomics Resource Centre Berhad: 0155 [BURSA: MGRC] [RIC: MGRC:KL] [BBG: MGRC:MK], http://www.mgrc.com.my/ Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More